Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics Limited has notified the market of the issue of 43.5 million unlisted options under an employee incentive scheme, with an exercise price of US$0.0057 and an expiry date of 13 January 2031. The options, which will not be quoted on the ASX, reflect the company’s continued use of equity incentives to align employees with shareholder interests and may contribute to future dilution if exercised, signaling an ongoing focus on incentivising key personnel during its development phase.
The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a biotechnology company listed on the ASX under the code ATH. The company operates in the life sciences sector, focusing on the development of therapeutic products, and uses equity-based incentive schemes as part of its capital management and employee remuneration strategy.
Average Trading Volume: 14,979,325
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$87M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.